Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire

被引：54

作者：

Chaix, ML ^{[1
]}

Ekouevi, DK ^{[1
]}

Rouet, F ^{[1
]}

Tonwe-Gold, B ^{[1
]}

Viho, I ^{[1
]}

Bequet, L ^{[1
]}

Peytavin, G ^{[1
]}

Toure, H ^{[1
]}

Menan, H ^{[1
]}

Leroy, V ^{[1
]}

Dabis, F ^{[1
]}

Rouzioux, C ^{[1
]}

机构：

[1] Univ Victor Segalen, INSERM U593, ISPED, F-33076 Bordeaux, France

来源：

JOURNAL OF INFECTIOUS DISEASES | 2006年 / 193卷 / 04期

关键词：

D O I：

10.1086/499966

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The frequency of resistance mutations was estimated in the cohort of Agence Nationale de Recherches sur le SIDA Ditrame Plus, a study that evaluated the combination of short-course zidovudine ( ZDV) plus lamivudine ( 3TC) and single-dose nevirapine ( SD-NVP) followed by 3 days of postpartum ZDV plus 3TC for the prevention of mother-to-child transmission of human immunodeficiency virus type 1 ( HIV-1). The frequency with which resistance mutations were detected in mothers at week 4 postpartum was 1.14% ( 95% confidence interval [ CI], 0.03% - 6.17%) for NVP and 8.33% ( 95% CI, 3.66% - 15.76%) for 3TC. In multivariate analysis, 3TC resistance was associated with a longer duration of ZDV plus 3TC prepartum prophylaxis (P = .009). This regimen, which is feasible in resource-limited settings, prevents most peripartum HIV-1 transmission and minimizes the development of NVP resistance.

引用

页码：482 / 487

页数：6

共 15 条

[1]

[Anonymous], 2004, ANT DRUGS TREAT PREG

[2]

CHAIX ML, 2004, ANTIVIR THER, V9, pS176

[3] Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group protocol 316 [J].

Cunningham, CK ;

Chaix, ML ;

Rekacewicz, C ;

Britto, P ;

Rouzioux, C ;

Gelber, RD ;

Dorenbaum, A ;

Delfraissy, JF ;

Bazin, B ;

Mofenson, L ;

Sullivan, JL .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) :181-188

[4]

Dabis F, 2005, AIDS, V19, P309

[5] Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP [J].

Eshleman, SH ;

Hoover, DR ;

Chen, S ;

Hudelson, SE ;

Guay, LA ;

Mwatha, A ;

Fiscus, SA ;

Mmiro, F ;

Musoke, P ;

Jackson, JB ;

Kumwenda, N ;

Taha, T .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :30-36

[6] Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) [J].

Eshleman, SH ;

Mracna, M ;

Guay, LA ;

Deseyve, M ;

Cunningham, S ;

Mirochnick, M ;

Musoke, P ;

Fleming, T ;

Fowler, MG ;

Mofenson, LM ;

Mmiro, F ;

Jackson, JB .

AIDS, 2001, 15 (15) :1951-1957

[7]

FELSENSTEIN J, 2001, PHYLIP VERSION 3 6 X

[8] Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated [J].

Johnson, JA ;

Li, JF ;

Morris, L ;

Martinson, N ;

Gray, G ;

McIntyre, J ;

Heneine, W .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :16-23

[9] Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy [J].

Jourdain, G ;

Ngo-Giang-Huong, N ;

Le Coeur, S ;

Bowonwatanuwong, C ;

Kantipong, P ;

Leechanachai, P ;

Ariyadej, S ;

Leenasirimakul, P ;

Hammer, S ;

Lallemant, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (03) :229-240

[10] Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand [J].

Lallemant, M ;

Jourdain, G ;

Le Coeur, S ;

Mary, JY ;

Ngo-Giang-Huong, N ;

Koetsawang, S ;

Kanshana, S ;

McIntosh, K ;

Thaineua, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (03) :217-228

← 1 2 →